Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions
ALGS Stock Forecast
Aligos Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a -68.59% downside from ALGS’s last price of $9.55) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
ALGS Price Target
ALGS Analyst Ratings
Aligos Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jan 06, 2023 | - | Piper Sandler | $3.00 | $1.22 | 146.91% | -68.59% |
Jan 06, 2023 | - | Jefferies | $3.00 | $0.99 | 203.03% | -68.59% |
Aligos Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $9.55 | $9.55 | $9.55 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Aug 19, 2024 | H.C. Wainwright | - | Buy | Initialise |
Jul 19, 2024 | Piper Sandler | Overweight | Overweight | Hold |
May 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jan 06, 2023 | Barclays | - | Equal-Weight | Downgrade |
Jan 06, 2023 | Wedbush | - | Neutral | Downgrade |
Jan 06, 2023 | Raymond James | - | Outperform | Downgrade |
Jan 06, 2023 | J.P. Morgan | - | Neutral | Downgrade |
Jan 06, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
Aligos Therapeutics Financial Forecast
Aligos Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $3.54M | $4.11M | $2.57M | $910.00K |
Avg Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.18M | $1.07M |
High Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.62M | $1.29M |
Low Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $1.75M | $857.42K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.65% | 5.47% | 1.18% | 0.85% |
Aligos Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
EBITDA | - | - | - | - | - | - | - | - | $-19.07M | $-22.68M | $-18.04M | $-34.57M | $-26.76M |
Avg Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-29.30M | $-31.51M |
High Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-23.44M | $-25.21M |
Low Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-35.15M | $-37.82M |
Surprise % | - | - | - | - | - | - | - | - | 38.14% | 52.75% | 120.28% | 1.18% | 0.85% |
Aligos Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
Net Income | - | - | - | - | - | - | - | - | $-18.04M | $-21.89M | $-18.62M | $-35.62M | $-27.67M |
Avg Forecast | $-20.55M | $-20.09M | $-19.13M | $-18.80M | $-9.34M | $-13.51M | $-25.06M | $-43.86M | $-74.41M | $-78.32M | $-90.86M | $-30.25M | $-32.59M |
High Forecast | $-20.55M | $-20.09M | $-19.13M | $-18.80M | $-9.34M | $2.83M | $-25.06M | $-17.87M | $-74.41M | $-78.32M | $-90.86M | $-24.20M | $-26.08M |
Low Forecast | $-20.55M | $-20.09M | $-19.13M | $-18.80M | $-9.34M | $-27.66M | $-25.06M | $-69.85M | $-74.41M | $-78.32M | $-90.86M | $-36.30M | $-39.11M |
Surprise % | - | - | - | - | - | - | - | - | 0.24% | 0.28% | 0.20% | 1.18% | 0.85% |
Aligos Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
SG&A | - | - | - | - | - | - | - | - | $6.44M | $7.12M | $5.26M | $6.45M | $5.78M |
Avg Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $5.32M | $2.61M |
High Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $6.38M | $3.13M |
Low Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $4.25M | $2.09M |
Surprise % | - | - | - | - | - | - | - | - | 1.06% | 1.36% | 2.88% | 1.21% | 2.22% |
Aligos Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
EPS | - | - | - | - | - | - | - | - | $-0.41 | $-0.51 | $-0.44 | $-0.84 | $-0.74 |
Avg Forecast | $-3.28 | $-3.21 | $-3.05 | $-3.00 | $-1.49 | $-2.16 | $-4.00 | $-7.00 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
High Forecast | $-3.28 | $-3.21 | $-3.05 | $-3.00 | $-1.49 | $0.45 | $-4.00 | $-2.85 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
Low Forecast | $-3.28 | $-3.21 | $-3.05 | $-3.00 | $-1.49 | $-4.41 | $-4.00 | $-11.15 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
Surprise % | - | - | - | - | - | - | - | - | 0.03% | 0.04% | 0.03% | 0.05% | 0.03% |
Aligos Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
NUVB | Nuvation Bio | $2.30 | $6.75 | 193.48% | Buy |
TIL | Instil Bio | $28.78 | $78.25 | 171.89% | Hold |
NXTC | NextCure | $1.33 | $3.00 | 125.56% | Buy |
ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
ACHL | Achilles Therapeutics | $1.02 | $2.00 | 96.08% | Buy |
ALGS | Aligos Therapeutics | $9.55 | $3.00 | -68.59% | Hold |
ALGS Forecast FAQ
Is Aligos Therapeutics a good buy?
No, according to 13 Wall Street analysts, Aligos Therapeutics (ALGS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 30.77% of ALGS's total ratings.
What is ALGS's price target?
Aligos Therapeutics (ALGS) average price target is $3 with a range of $3 to $3, implying a -68.59% from its last price of $9.55. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aligos Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ALGS stock, the company can go down by -68.59% (from the last price of $9.55 to the average price target of $3), down by -68.59% based on the highest stock price target, and down by -68.59% based on the lowest stock price target.
Can Aligos Therapeutics stock reach $14?
ALGS's average twelve months analyst stock price target of $3 does not support the claim that Aligos Therapeutics can reach $14 in the near future.
What are Aligos Therapeutics's analysts' financial forecasts?
Aligos Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.73M (high $1.73M, low $1.73M), average EBITDA is $-346K (high $-346K, low $-346K), average net income is $-47.913M (high $-31.571M, low $-62.055M), average SG&A $4.21M (high $4.21M, low $4.21M), and average EPS is $-7.647 (high $-5.039, low $-9.904). ALGS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.33M (high $1.33M, low $1.33M), average EBITDA is $-267K (high $-267K, low $-267K), average net income is $-78.575M (high $-78.575M, low $-78.575M), average SG&A $3.25M (high $3.25M, low $3.25M), and average EPS is $-12.54 (high $-12.54, low $-12.54).
Did the ALGS's actual financial results beat the analysts' financial forecasts?
Based on Aligos Therapeutics's last annual report (Dec 2022), the company's revenue was $13.91M, beating the average analysts forecast of $5.08M by 173.57%. Apple's EBITDA was $-97.58M, beating the average prediction of $-29.875M by 226.62%. The company's net income was $-96.046M, missing the average estimation of $-199M by -51.84%. Apple's SG&A was $26.41M, beating the average forecast of $12.38M by 113.40%. Lastly, the company's EPS was $-2.25, missing the average prediction of $-45.188 by -95.02%. In terms of the last quarterly report (Dec 2022), Aligos Therapeutics's revenue was $3.54M, beating the average analysts' forecast of $2.15M by 64.51%. The company's EBITDA was $-22.682M, beating the average prediction of $-430K by 5174.90%. Aligos Therapeutics's net income was $-21.886M, missing the average estimation of $-78.324M by -72.06%. The company's SG&A was $7.12M, beating the average forecast of $5.23M by 36.01%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-12.5 by -95.92%